AbbVie announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of atogepant for the prophylaxis of migraine in adults who have four or more migraine days per month. If approved, AbbVie will be the only company to offer a once daily oral calcitonin gene-related peptide receptor antagonist treatment spanning both episodic and chronic migraine in the European Union.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
